Verona Pharma plc (VRNA)
- Previous Close
67.53 - Open
67.29 - Bid 67.37 x 100
- Ask 67.71 x 400
- Day's Range
66.13 - 68.23 - 52 Week Range
11.39 - 74.18 - Volume
751,269 - Avg. Volume
1,454,338 - Market Cap (intraday)
5.742B - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-2.00 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
94.10
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
www.veronapharma.comRecent News: VRNA
View More
Performance Overview: VRNA
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRNA
View MoreValuation Measures
Market Cap
5.75B
Enterprise Value
5.59B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.08
Price/Book (mrq)
25.39
Enterprise Value/Revenue
47.20
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-138.31%
Return on Assets (ttm)
-20.64%
Return on Equity (ttm)
-72.61%
Revenue (ttm)
118.53M
Net Income Avi to Common (ttm)
-163.94M
Diluted EPS (ttm)
-2.00
Balance Sheet and Cash Flow
Total Cash (mrq)
401.42M
Total Debt/Equity (mrq)
107.63%
Levered Free Cash Flow (ttm)
-69.15M